The ALL Hub was pleased to speak with Wendy Stock, the University of Chicago, US. We asked, What is the rationale for the use of pediatric-inspired asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)?
In this interview, Stock reviews the clinical evidence and key considerations supporting this treatment approach in the AYA patient population.
This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
","author_name":"Scientific Education Support"}